title: Mechanisms of DHA transport to the brain and potential therapy to neurodegenerative diseases.
abstract: Docosahexaenoic acid (DHA; 22:6 ω-3) is highly enriched in the brain and is required for proper brain development and function. Its deficiency has been shown to be linked with the emergence of neurological diseases. Dietary ω-3 fatty acid supplements including DHA have been suggested to improve neuronal development and enhance cognitive functions. However, mechanisms of DHA incorporation in the brain remain to be fully understood. Findings suggested that DHA is better incorporated when esterified within lysophospholipid rather than under its non-esterified form. Furthermore, DHA has the potential to be converted into diverse oxylipins with potential neuroprotective effects. Since DHA is poorly synthesized de novo, targeting the brain with specific carriers of DHA might provide novel therapeutic approaches to neurodegenerative diseases.
authors: Univ Lyon, INSA-Lyon, Inserm UMR 1060, Inra UMR 1397, CarMeN Laboratory, IMBL, Villeurbanne F-69621, France; Tohoku University Grad. Sch. of Med., Center for Neuroscience, ART, Dept. of Developmental Neuroscience, Sendai, Japan.
authors: Amanda
authors: A
authors: Lo Van
authors: Tohoku University Grad. Sch. of Med., Center for Neuroscience, ART, Dept. of Developmental Neuroscience, Sendai, Japan.
authors: Nobuyuki
authors: N
authors: Sakayori
authors: Univ Lyon, INSA-Lyon, Inserm UMR 1060, Inra UMR 1397, CarMeN Laboratory, IMBL, Villeurbanne F-69621, France.
authors: Mayssa
authors: M
authors: Hachem
authors: Univ Lyon, INSA-Lyon, Inserm UMR 1060, Inra UMR 1397, CarMeN Laboratory, IMBL, Villeurbanne F-69621, France.
authors: Mounir
authors: M
authors: Belkouch
authors: Univ Lyon, INSA-Lyon, Inserm UMR 1060, Inra UMR 1397, CarMeN Laboratory, IMBL, Villeurbanne F-69621, France.
authors: Madeleine
authors: M
authors: Picq
authors: Univ Lyon, INSA-Lyon, Inserm UMR 1060, Inra UMR 1397, CarMeN Laboratory, IMBL, Villeurbanne F-69621, France.
authors: Michel
authors: M
authors: Lagarde
authors: Tohoku University Grad. Sch. of Med., Center for Neuroscience, ART, Dept. of Developmental Neuroscience, Sendai, Japan.
authors: Noriko
authors: N
authors: Osumi
authors: Univ Lyon, INSA-Lyon, Inserm UMR 1060, Inra UMR 1397, CarMeN Laboratory, IMBL, Villeurbanne F-69621, France. Electronic address: nathalie.bernoud-hubac@insa-lyon.fr.
authors: Nathalie
authors: N
authors: Bernoud-Hubac
mesh_terms: D000818:Animals; D001692:Biological Transport; D001812:Blood-Brain Barrier / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D004281:Docosahexaenoic Acids / Q000008:administration & dosage / Q000378:metabolism*; D006801:Humans; D008244:Lysophosphatidylcholines / Q000378:metabolism; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000378:metabolism*; D010713:Phosphatidylcholines / Q000378:metabolism
chemical_list: C000603131:1-acetyl-2-docosahexaenoyl-glycerophosphocholine; D008244:Lysophosphatidylcholines; D018696:Neuroprotective Agents; D010713:Phosphatidylcholines; C090324:docosahexaenoyl lysophosphatidylcholine; D004281:Docosahexaenoic Acids
keywords: Blood-brain-barrier; Brain; Docosahexaenoic acid; Neuroprotection; Phospholipids; Transport